HealthRX.com · Printable medication review sheet
Peptide schedule check: the label's interval against what you were told
List each injectable peptide you use or were offered, write how often the FDA label says to use it (if a label exists) and how often you were told, and bring any mismatch to your prescriber or pharmacist. Label facts for four approved products are printed for comparison.
Each injectable peptide you use or were offered
Write 'no label' if the product is compounded or not FDA-approved.
| Product name as printed | FDA-approved with a US label? | How often the label says | How often you were told | Who told you | Same or different? |
|---|---|---|---|---|---|
How often four FDA labels say to use the product
- Wegovy injection: once weekly, on the same day each week, at any time of day.[1]
- Saxenda: once daily at any time of day. If more than 3 days pass since the last dose, the label says to restart at 0.6 mg and step up again.[2]
- EGRIFTA SV: once daily.[3]
- Vyleesi: as needed, at least 45 minutes before sexual activity; no more than one dose within 24 hours, and more than 8 doses a month is not recommended.[4]
What FDA says about two unapproved peptides on this page
- CJC-1295: FDA has identified serious adverse events including increased heart rate and a systemic vasodilatory reaction.[5]
- GHRP-6: in FDA's 503B category 2 since September 29, 2023, for a possible immune-reaction risk.[5]
Before you change how often you inject
- Find the dosing section of the label, or the pharmacy's written directions, and read it
- Check whether the product is FDA-approved or compounded
- Ask the prescriber before changing the interval or skipping a dose
- Record the date and time of every injection
- Note any side effect and the day it started
Questions for your prescriber or pharmacist
- Is this an FDA-approved product, and where does its schedule come from?
- If it is compounded, which FDA rule allows the pharmacy to use this substance?
- What should I do if I miss a dose, according to the label or your written directions?
- I compete in a tested sport: is this substance on the prohibited list?
Sources for the facts on this sheet
- Novo Nordisk, via DailyMed. Wegovy (semaglutide) injection, for subcutaneous use; Wegovy (semaglutide) tablets, for oral use: prescribing information. Effective 2026-06-18. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- Novo Nordisk, via DailyMed. Saxenda (liraglutide) injection, for subcutaneous use: prescribing information. Effective 2026-02-25. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
- Theratechnologies, via DailyMed. EGRIFTA SV (tesamorelin) for injection, for subcutaneous use: prescribing information. Effective 2026-07-29. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- Cosette Pharmaceuticals, via DailyMed. VYLEESI (bremelanotide injection), for subcutaneous use: prescribing information. Effective 2025-11-13. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed 2026-10-19. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.